(MENAFN- GlobeNewsWire - Nasdaq) The prenatal and newborn genetic testing market is expanding due to technological advancements in non-invasive methods, rising awareness of genetic disorders, and supportive policies. Key opportunities include increased adoption of NGS and cfDNA technologies, growing demand in Asia Pacific, and insurance coverage expansion. Challenges persist with high costs and ethical issues.

Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The "Prenatal and Newborn Genetic Testing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033" report has been added to ResearchAndMarkets's offering.
The global prenatal and newborn genetic testing market is projected to expand at a CAGR of 12.7% from 2025 to 2033, fueled by rising demand for early disease detection, advances in sequencing technologies, and growing awareness of genetic disorders.

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.
Prenatal and newborn testing enables early identification of chromosomal abnormalities, inherited conditions, and metabolic disorders, facilitating timely interventions and improving long-term health outcomes. Increasing adoption of non-invasive testing methods and integration of genetic testing into routine prenatal care are further supporting market expansion.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Rising Awareness and Technological Innovation Driving Growth
The adoption of next-generation sequencing (NGS), cell-free DNA (cfDNA) testing, and advanced spectrometry techniques is improving diagnostic accuracy and reducing risks associated with traditional invasive methods. Growing emphasis on personalized medicine, coupled with parental awareness about genetic diseases, is pushing demand for both prenatal screening and newborn testing programs. Supportive government initiatives, expansion of insurance coverage for genetic tests, and strategic partnerships between diagnostic firms and healthcare providers are accelerating market penetration.
High Costs and Ethical Concerns Present Challenges
Despite strong growth drivers, barriers such as the high cost of advanced genetic tests, limited access in low-income regions, and ethical debates surrounding prenatal testing continue to hinder adoption. Infrastructural gaps and shortages of trained professionals further limit market reach in developing economies. However, the increasing affordability of sequencing technologies, growing investments in laboratory infrastructure, and expansion of tele-genetics services are expected to reduce these challenges over time.
Market Segmentation by Product and Services
The market is segmented into kits and reagents and services. In 2024, services dominated, supported by growing demand for laboratory-based testing and diagnostic expertise. Kits and reagents are expanding rapidly, driven by the rising trend of decentralized and hospital-based genetic testing solutions.
Market Segmentation by Technology
By technology, the market includes next-generation sequencing (NGS), cell-free DNA (cfDNA), array-comparative genomic hybridization (aCGH), fluorescence in-situ hybridization (FISH), spectrometry, whole exome sequencing (WES), and other technologies. In 2024, cfDNA testing held the largest share due to its non-invasive nature and reliability in detecting chromosomal abnormalities such as Down syndrome.

NGS is witnessing strong growth, enabling high-throughput and comprehensive genetic analysis. aCGH and FISH remain important tools for chromosomal and structural analysis, while WES is increasingly adopted for rare genetic disorders. Spectrometry and other technologies continue to support niche diagnostic needs.
Regional Insights
In 2024, North America led the market, driven by strong adoption of advanced genetic tests, favorable reimbursement policies, and leading presence of biotechnology companies. Europe followed, with countries such as Germany, France, and the UK implementing national prenatal and newborn screening programs. Asia Pacific is the fastest-growing region, with China and India showing rising demand due to expanding healthcare infrastructure and government-backed newborn screening initiatives. Latin America and Middle East & Africa are emerging regions, where affordability and access remain challenges but increasing healthcare investments are opening opportunities.
Competitive Landscape
The 2024 market was characterized by a mix of global diagnostics leaders and specialized genetic testing companies. Illumina, Thermo Fisher Scientific, and Agilent led with comprehensive sequencing and molecular diagnostics platforms. Natera, Myriad Genetics, and Revvity specialized in prenatal screening and hereditary condition testing. LabCorp and Eurofins provided broad laboratory-based genetic services across global markets.

BGI Group, Fulgent Genetics, Trivitron Healthcare, and Genes2me strengthened regional presence with accessible genetic testing solutions. Companies such as BillionToOne, Yourgene Health, Retrogen, LaCAR, and Genelab (Clevergene) contributed to niche markets with innovative test offerings. Aetna played a supporting role in insurance coverage, increasing test accessibility. Competitive differentiation is driven by accuracy, non-invasive technologies, turnaround time, affordability, and global distribution networks.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Prenatal and Newborn Genetic Testing market?
• What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2033.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Prenatal and Newborn Genetic Testing market?
• Which is the largest regional market for Prenatal and Newborn Genetic Testing market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Prenatal and Newborn Genetic Testing market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Prenatal and Newborn Genetic Testing market worldwide?

Companies Featured

• Aetna
• Agilent
• BGI Group
• BillionToOne
• CENTOGENE
• Eurofins
• Fulgent Genetics
• Genes2me
• Illumina
• Myriad Genetics
• Natera
• Thermo Fisher Scientific
• Trivitron Healthcare

Market Segmentation

Product and Services

• Kits and reagents
• Services
• Test Type
• Prenatal test

Screening tests

• Amniocentesis
• Carrier screening
• Chorionic villus sampling (CVS)
• Critical congenital heart defect (CCHD)
• Diagnostic
• Hearing screening
• Heel prick test
• Newborn screening
• Non-invasive prenatal testing (NIPT)
• Nuchal translucency ultrasound
• Other newborn screening tests
• Serum screening

Technology

• Next-generation sequencing (NGS)
• Cell-free DNA (cfDNA)
• Array-comparative genomic hybridization (aCGH)
• Fluorescence in-situ hybridization (FISH)
• Spectrometry
• Whole exome sequencing (WES)
• Other technologies

Application

• Down syndrome
• Phenylketonuria (PKU)
• Cystic fibrosis (CF)
• Sickle cell anemia
• Congenital hypothyroidism
• Pendred syndrome
• Other applications

End Use

• Hospitals
• Diagnostic laboratories
• Maternity and specialty clinics
• Other end use

Region Segment (2023 - 2033; US$ Million)

• North America
• U.S.
• Canada
• Rest of North America
• UK and European Union
• UK
• Germany
• Spain
• Italy
• France
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• Africa
• Rest of Middle East and Africa

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN15102025004107003653ID1110199748